Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Avigan Hits Primary Goal for Novel Coronavirus, Filing Eyed in October: Fujifilm
September 24, 2020
- Lenvima/Keytruda Combo Shows around 30% ORR in Triple Negative Breast Cancer, Ovarian Cancer: PII
September 24, 2020
- Keytruda’s 1st Line Gastric Cancer Submission Pulled in Japan
September 23, 2020
- 42 Nippon Chemiphar Reps to Hit Exit under Voluntary Redundancy
September 23, 2020
- Sanofi’s Dupixent Adds Pen Formulation in Japan
September 23, 2020
- Lucentis Biosimilar Filed in Japan; Senju/Gene Techno Eye 2021 Approval
September 23, 2020
- Kyowa Kirin Sees Steady Switch to Nesp Biosame, but Biosimilars Closing in at Full Steam
September 18, 2020
- Santen Gobbles Up US Ophthalmic Player for US$225 Million
September 18, 2020
- Towa, Nichi-Iko Recalling Some Metformin Products over Carcinogen Risks, Follow 2 Makers
September 17, 2020
- Nichi-Iko to Resume Normal Shipments of Cefazolin Starting October 1
September 17, 2020
- Takeda Opens New Manufacturing Site for Cell Therapy Products in Boston
September 17, 2020
- Takeda to Offload TachoSil to Corza Health
September 17, 2020
- Amgen Files Erenumab for Migraine Prevention in Japan
September 17, 2020
- SanBio to Start Talks with PMDA over Late-Stage Study of SB623 in Ischemic, Hemorrhagic Strokes: COO
September 17, 2020
- Prescriptions for Respiratory Meds, Antibiotics Down Over 30% in August: Survey
September 16, 2020
- Daiichi Sankyo Begins PII Study of ADC Patritumab for HER3-Positive Colorectal Cancer
September 16, 2020
- Novartis’ Mayzent now Available in Japan for Secondary Progressive MS
September 15, 2020
- J-TEC Files Mucosal Cell Sheet for Corneal Epithelial Stem Cell Deficiency in Japan
September 15, 2020
- Incyte Files Japan NDA for Pemigatinib for Cholangiocarcinoma
September 15, 2020
- Lilly Japan to Run Its First Voluntary Redundancy Program, 10% of Sales Force Targeted?
September 15, 2020
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…